BCM
SYRE icon

Bridgeway Capital Management’s Spyre Therapeutics SYRE Stock Holding History

Bridgeway Capital Management’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-36,100
Closed -$849K – 1316
2024
Q2 		$849K Buy
+36,100
New +$1.22M 0.02% 733
2023
Q2 		– Sell
-6,000
Closed -$43.5K – 1446
2023
Q1 		$43.5K Hold
6,000
– – ﹤0.01% 1318
2022
Q4 		$67.5K Buy
+6,000
New +$108K ﹤0.01% 1267
2022
Q3 		– Sell
-1,946
Closed -$25K – 1450
2022
Q2 		$25K Sell
1,946
-2,974
-60% -$104K ﹤0.01% 1307
2022
Q1 		$283K Buy
+4,920
New +$413K 0.01% 1096
2020
Q2 		– Sell
-4,580
Closed -$534K – 1397
2020
Q1 		$534K Buy
4,580
+480
+12% +$81.6K 0.01% 740
2019
Q4 		$783K Hold
4,100
– – 0.01% 802
2019
Q3 		$788K Hold
4,100
– – 0.01% 794
2019
Q2 		$702K Hold
4,100
– – 0.01% 866
2019
Q1 		$825K Hold
4,100
– – 0.01% 833
2018
Q4 		$768K Hold
4,100
– – 0.01% 839
2018
Q3 		$981K Buy
4,100
+100
+3% +$23.4K 0.01% 887
2018
Q2 		$1.06M Hold
4,000
– – 0.01% 862
2018
Q1 		$992K Hold
4,000
– – 0.01% 841
2017
Q4 		$541K Hold
4,000
– – 0.01% 1067
2017
Q3 		$474K Hold
4,000
– – 0.01% 1109
2017
Q2 		$384K Buy
+4,000
New +$553K ﹤0.01% 1156

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bridgeway Capital Management's SYRE Position: Q3 2024 in Review

Bridgeway Capital Management sold out of Spyre Therapeutics (SYRE) in Q3 2024, closing a stake of 36,100 shares — an estimated $849K sold.

Bridgeway Capital Management first reported a position in SYRE in Q2 2017 and held it in 17 quarters. The position peaked at $1.06M in Q2 2018. 119 funds tracked by Wall St. Rank hold SYRE as of Q3 2024.

  • Bridgeway Capital Management reported no remaining Spyre Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Bridgeway Capital Management sold 36,100 Spyre Therapeutics shares in Q3 2024, an estimated $849K.
  • Bridgeway Capital Management first reported a position in Spyre Therapeutics in Q2 2017 and held it in 17 quarters.
  • Bridgeway Capital Management's Spyre Therapeutics position peaked at $1.06M in Q2 2018.
  • 119 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q3 2024.

Based on Bridgeway Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.